![PRD_000642 PRD_000642](https://data.pdbj.org/pdbjplus/data/cc/svg/A03.svg) | PRD_000642 | Name: | (10R,20R,23R)-1-[(2S,3S,4R,5R)-5-(6-amino-9H-purin-9-yl)-3,4-dihydroxytetrahydrofuran-2-yl]-20,23-bis(3-carbamimidamido
propyl)-10-methyl-1,8,11,18,21-pentaoxo-2,9,12,19,22-pentaazatetracosan-24-amide | Formula: | C37 H63 N17 O9 | Definition date: | 2012-12-12 | Last modified: | 2023-11-03 |
|
![PRD_002255 PRD_002255](https://data.pdbj.org/pdbjplus/data/cc/svg/7HY.svg) | PRD_002255 | Name: | N,N-diethyl-N~2~-(3-phenylpropanoyl)-L-asparaginyl-N-[(naphthalen-1-yl)methyl]-L-alaninamide | Formula: | C31 H38 N4 O4 | Definition date: | 2020-08-12 | Last modified: | 2023-11-03 |
|
![PRD_000645 PRD_000645](https://data.pdbj.org/pdbjplus/data/cc/svg/ARX.svg) | PRD_000645 | Name: | (2S,3S,4R,5R)-5-(6-amino-9H-purin-9-yl)-N-(6-{[(1R)-4-carbamimidamido-1-{[(1R)-4-carbamimidamido-1-carbamoylbutyl]carbamoyl}butyl]amino}-6-oxohexyl)-3,4-dihydroxytetrahydrofuran-2-carboxamide | Formula: | C28 H47 N15 O7 | Definition date: | 2012-12-12 | Last modified: | 2023-11-03 |
|
![PRD_002256 PRD_002256](https://data.pdbj.org/pdbjplus/data/cc/svg/7HZ.svg) | PRD_002256 | Name: | N-tert-butoxy-N~2~-(5-methyl-1,2-oxazole-3-carbonyl)-L-asparaginyl-O-methyl-N-[(naphthalen-1-yl)methyl]-L-serinamide | Formula: | C28 H35 N5 O7 | Definition date: | 2017-01-11 | Last modified: | 2023-11-03 |
|
![PRD_002257 PRD_002257](https://data.pdbj.org/pdbjplus/data/prd/svg/PRD_002257.svg) | PRD_002257 | Name: | Globomycin | Formula: | C32 H57 N5 O9 | Definition date: | 2019-08-28 | Last modified: | 2023-11-03 |
|
![PRD_002282 PRD_002282](https://data.pdbj.org/pdbjplus/data/prd/svg/PRD_002282.svg) | PRD_002282 | Name: | (3S,6S,9S,15aR)-6,9-dibenzyl-3-{6,6-dihydroxy-6-[(2S)-oxiran-2-yl]hexyl}octahydro-2H-pyrido[1,2-a][1,4,7,10]tetraazacyclododecine-1,4,7,10(3H,12H)-tetrone | Formula: | C34 H44 N4 O7 | Definition date: | 2017-09-13 | Last modified: | 2023-11-03 |
|
![PRD_002285 PRD_002285](https://data.pdbj.org/pdbjplus/data/prd/svg/PRD_002285.svg) | PRD_002285 | Name: | N~2~-[(2S)-2-{[3-(6-chloro-1,3-benzothiazol-2-yl)-N-propanoyl-L-alanyl]amino}-2-cyclopentylacetyl]-N-[(4R)-3,4-dihydro-2H-1-benzopyran-4-yl]-N~6~,N~6~-dimethyl-L-lysinamide | Formula: | C37 H49 Cl N6 O5 S | Definition date: | 2018-02-28 | Last modified: | 2023-11-03 |
|
![PRD_000672 PRD_000672](https://data.pdbj.org/pdbjplus/data/prd/svg/PRD_000672.svg) | PRD_000672 | Name: | CBZ-ASP-GLU-VAL-azaASP-EP-CO-NH-CH2PH | Formula: | C35 H44 N6 O14 | Definition date: | 2012-12-12 | Last modified: | 2023-11-03 |
|
![PRD_002289 PRD_002289](https://data.pdbj.org/pdbjplus/data/prd/svg/PRD_002289.svg) | PRD_002289 | Name: | 3-[(3R,6S,9S,12S,15S,18S,21S,24R,27S)-21-(2-amino-2-oxoethyl)-9-(3-aminopropyl)-3,24,27-tribenzyl-15-[(4-hydroxyphenyl)methyl]-6-(2-methylpropyl)-2,5,8,11,14,17,20,23,26,29-decaoxo-12-(propan-2-yl)-2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19,20,21,22,23,24,25,26,27,28,29-octacosahydro-1H-1,4,7,10,13,16,19,22,25,28-benzodecaazacyclohentriacontin-18-yl]propanamide | Formula: | C68 H85 N13 O13 | Definition date: | 2020-08-12 | Last modified: | 2023-11-03 |
|
![PRD_000673 PRD_000673](https://data.pdbj.org/pdbjplus/data/prd/svg/PRD_000673.svg) | PRD_000673 | Name: | CBZ-ASP-GLU-VAL-azaASP-EP-COO-CH2PH | Formula: | C35 H43 N5 O15 | Definition date: | 2012-12-12 | Last modified: | 2023-11-03 |
|
![PRD_000674 PRD_000674](https://data.pdbj.org/pdbjplus/data/prd/svg/PRD_000674.svg) | PRD_000674 | Name: | CBZ-ASP-GLU-VAL-azaASP-EP-CO-N(CH2PH)2 | Formula: | C42 H50 N6 O14 | Definition date: | 2012-12-12 | Last modified: | 2023-11-03 |
|
![PRD_002290 PRD_002290](https://data.pdbj.org/pdbjplus/data/prd/svg/PRD_002290.svg) | PRD_002290 | Name: | 4-[(3R,6S,9S,12S,15S,18S,21S,24R,27S)-21-(2-amino-2-oxoethyl)-9-(3-aminopropyl)-3,24,27-tribenzyl-15-[(4-hydroxyphenyl)methyl]-6-(2-methylpropyl)-2,5,8,11,14,17,20,23,26,29-decaoxo-12-(propan-2-yl)-2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19,20,21,22,23,24,25,26,27,28,29-octacosahydro-1H-1,4,7,10,13,16,19,22,25,28-benzodecaazacyclohentriacontin-18-yl]butan-1-aminium | Formula: | C69 H90 N13 O12 | Definition date: | 2020-08-12 | Last modified: | 2023-11-03 |
|
![PRD_002314 PRD_002314](https://data.pdbj.org/pdbjplus/data/prd/svg/PRD_002314.svg) | PRD_002314 | Name: | INNN(ABU) Cyclic peptide inhibitor | Formula: | C22 H36 N8 O8 | Definition date: | 2019-04-17 | Last modified: | 2023-11-03 |
|
![PRD_000727 PRD_000727](https://data.pdbj.org/pdbjplus/data/prd/svg/PRD_000727.svg) | PRD_000727 | Name: | PYOVERDIN G173 Fe Complex | Formula: | C49 H66 Fe N13 O21 | Description: | IN IRON-DEFICIENT CONDITIONS, PSEUDOMONAS
AERUGINOSA SECRETES A MAJOR FLUORESCENT
SIDEROPHORE NAMED PYOVERDIN (PVD),
WHICH AFTER CHELATING IRON(III) IS TRANSPORTED
BACK INTO THE CELL VIA ITS OUTER MEMBRANE RECEPTOR
FPVA. FPVA IS A TONB-DEPENDENT TRANSPORT PROTEIN
AND HAS THE ABILITY TO BIND PVD IN ITS APO-
OR IRON-LOADED FORM. | Definition date: | 2012-12-12 | Last modified: | 2023-11-03 |
|
![PRD_002338 PRD_002338](https://data.pdbj.org/pdbjplus/data/cc/svg/KD7.svg) | PRD_002338 | Name: | N-(3-phenylpropanoyl)-3-(1,3-thiazol-4-yl)-L-alanyl-N-[(1S,2S)-1-(1,3-benzothiazol-2-yl)-5-carbamimidamido-1-hydroxypentan-2-yl]-L-valinamide | Formula: | C33 H42 N8 O4 S2 | Definition date: | 2019-10-02 | Last modified: | 2023-11-03 |
|
![PRD_000770 PRD_000770](https://data.pdbj.org/pdbjplus/data/prd/svg/PRD_000770.svg) | PRD_000770 | Name: | (5S, 8R, 11S)-14-[4-(BENZYLOXY)-4-OXOBUTANOYL]-8-(2-CARBOXYETHYL)-5-(CARBOXYMETHYL)-11-
(1-METHYLETHYL)-3,6,9,12-TETRAOXO-1-PHENYL-2-OXA-4,7,10,13,14-PENTAAZAHEXADECAN-16-OIC ACID | Formula: | C35 H43 N5 O14 | Definition date: | 2012-12-12 | Last modified: | 2023-11-03 |
|
![PRD_002350 PRD_002350](https://data.pdbj.org/pdbjplus/data/prd/svg/PRD_002350.svg) | PRD_002350 | Name: | INHIBITOR ARC-1415 | Formula: | C55 H106 N30 O8 | Definition date: | 2021-08-04 | Last modified: | 2023-11-03 |
|
![PRD_000781 PRD_000781](https://data.pdbj.org/pdbjplus/data/prd/svg/PRD_000781.svg) | PRD_000781 | Name: | Thr-Asp-F-amidine | Formula: | C17 H29 F N6 O7 | Definition date: | 2012-12-12 | Last modified: | 2023-11-03 |
|
![PRD_000785 PRD_000785](https://data.pdbj.org/pdbjplus/data/prd/svg/PRD_000785.svg) | PRD_000785 | Name: | Largazole | Formula: | C21 H29 N4 O4 S3 | Definition date: | 2012-12-12 | Last modified: | 2023-11-03 |
|
![PRD_002363 PRD_002363](https://data.pdbj.org/pdbjplus/data/prd/svg/PRD_002363.svg) | PRD_002363 | Formula: | C73 H120 N20 O13 | Definition date: | 2020-08-12 | Last modified: | 2023-11-03 |
|
![PRD_002365 PRD_002365](https://data.pdbj.org/pdbjplus/data/prd/svg/PRD_002365.svg) | PRD_002365 | Name: | phazolicin | Formula: | C74 H104 N29 O27 S3 | Definition date: | 2020-08-12 | Last modified: | 2023-11-03 |
|
![PRD_002369 PRD_002369](https://data.pdbj.org/pdbjplus/data/prd/svg/PRD_002369.svg) | PRD_002369 | Name: | ecumicin | Formula: | C83 H135 N14 O17 | Definition date: | 2020-05-13 | Last modified: | 2023-11-03 |
|
![PRD_002390 PRD_002390](https://data.pdbj.org/pdbjplus/data/prd/svg/PRD_002390.svg) | PRD_002390 | Name: | Papain-like protease peptide inhibitor VIR251 | Formula: | C22 H33 N5 O7 | Definition date: | 2020-05-20 | Last modified: | 2023-11-03 |
|
![PRD_002391 PRD_002391](https://data.pdbj.org/pdbjplus/data/prd/svg/PRD_002391.svg) | PRD_002391 | Name: | covalently bound calpain inhibitor II | Formula: | C19 H37 N3 O4 S | Definition date: | 2020-06-17 | Last modified: | 2023-11-03 |
|
![PRD_002392 PRD_002392](https://data.pdbj.org/pdbjplus/data/prd/svg/PRD_002392.svg) | PRD_002392 | Name: | UAW246 | Formula: | C25 H36 N4 O6 | Definition date: | 2020-06-17 | Last modified: | 2023-11-03 |
|